Before tablet compression with Feizhucai Veterinary Grade API is initiated, the API lot is screened through a USP <786> sieve stack to confirm D90 ≤ 250 µm; oversize crystals are reduced in a screen mill fitted with a 0.8 mm stainless-steel screen and operated at 2,500–3,200 rpm. The milled API is then blended with microcrystalline cellulose, lactose monohydrate, crospovidone, and colloidal silicon dioxide in a 600 L bin blender at 20–25 rpm for 15–20 min. Magnesium stearate is screened through a 600 µm sieve and added last at 0.25–1.0% w/w; lubrication is limited to 3–5 min because magnesium stearate above 1.5% w/w has been observed on production batches to increase disintegration time under Ph. Eur. 2.9.1 beyond 15 min. Compression on a 27-station rotary tablet press with 9.5 mm round concave tooling is run at 15–25 kN main compression force and 60–80 rpm turret speed; tablet hardness is held at 60–90 N and friability below 0.8% per Ph. Eur. 2.9.7. Uniformity of dosage units is tested according to USP <905> with an acceptance value not exceeding 15.0. Dissolution testing uses USP <711> Apparatus 2 at 75 rpm in 900 mL of 0.1 N hydrochloric acid at 37.0 ± 0.5 °C; the Q value is taken from the approved regulatory specification and is not assigned from excipient behaviour alone. If the Feizhucai API batch shows a Carr index above 28 or a Hausner ratio above 1.4, direct compression is replaced by roller compaction at roll pressure 40–70 bar and 1.0 mm screen milling. The compression suite is maintained at 45–50% RH, and granule moisture by loss on drying at 105 °C is controlled at ≤ 2.0% w/w; published stability data for this specific API in humid excipient matrices is limited, so aluminium-aluminium blister packaging is specified when the moisture-vapour transmission rate exceeds 0.1 g/m²/day. The terminal product is an immediate-release veterinary tablet for companion animals.

What Limits Sterile Filtration Throughput in Injectable Solutions of Feizhucai Veterinary Grade API?

Injectable solution manufacture with Feizhucai Veterinary Grade API begins with dissolution in Water for Injection at 20–25 °C inside a closed stainless-steel vessel with bottom agitation. The pH is adjusted with 0.1 N hydrochloric acid or sodium hydroxide only after API addition; adjustments before API addition are avoided because local pH extremes can generate impurities before the active is fully solvated. A nitrogen overlay at 0.2–0.5 bar is applied when forced degradation studies identify oxidative sensitivity. Sodium metabisulfite is not introduced without stability confirmation because sulfur dioxide can react with carbonyl-containing APIs and form unidentified related substances. The bulk solution is passed through a 0.45 µm polyethersulfone prefilter and then through a 0.22 µm PVDF or PES sterilizing filter per ASTM F838-20; transmembrane pressure is limited to 1.0 bar for PES and 1.5 bar for PVDF to prevent filter rupture and downstream aerosol contamination. Pre-filtration bioburden is controlled at ≤ 10 CFU/100 mL under 21 CFR 211.113(a); exceeding this boundary triggers re-filtration and an investigation into the prefilter load. Filter integrity is tested before and after use by bubble point or forward-flow diffusion against the supplier minimum intrusion values recorded in the batch record. Terminal steam sterilization at 121 °C for 15 min is selected only when the resulting API degradation products remain below 0.5%; otherwise aseptic filling in an ISO 14644-1 Class 5 zone is used. The finished injectable for cattle and swine must meet USP <1> injectable product requirements, sterility by USP <71>, endotoxin limits by USP <85>, and particulate matter by USP <788>. Incompatibility with rubber stoppers is evaluated by headspace gas chromatography; volatile extractives from bromobutyl stoppers are controlled to ≤ 0.1% w/w total extractables in the finished solution, and siliconized stoppers are qualified at the minimum silicone level that still permits machinability on the filling line.

On a dosator-type capsule filling line, powder flow governs Feizhucai Veterinary Grade API capsule fill-weight variation more directly than chemical assay. If the blend Hausner ratio exceeds 1.35 or the Carr index exceeds 30, the filling machine produces fill-weight RSD above 5% even when the API assay is within specification. The API is therefore dry-milled or dry-granulated to a D90 of 180–250 µm and then blended with lactose monohydrate, pregelatinized starch, and 0.25% w/w sodium stearyl fumarate in a tumbling mixer at 18–22 rpm for 12–15 min. The blend is filled into hard gelatin or HPMC capsules at 20–25 °C and 40–50% RH; fill weight is monitored every 15 min by weight sorting, and the individual fill weight acceptance is derived from the approved target rather than a universal pharmacopeial limit. Dissolution of immediate-release capsules is tested with USP <711> Apparatus 1 at 100 rpm in 900 mL 0.1 N hydrochloric acid. Gelatin cross-linking is avoided by holding filling-room RH below 50% and by specifying the absence of aldehyde impurities in the API and excipients; if aldehyde-related crosslinking is suspected, dissolution is repeated after addition of pepsin according to the general chapter. Capsule moisture is controlled with silica gel desiccant packs when the package is exposed to tropical humidity. The terminal product is an oral capsule for equine or small-ruminant administration in white opaque HDPE bottles with induction-sealed closures to limit moisture ingress.

Water-Soluble Powder Dispersion and Carry-Over in Broiler Drinking Lines

A water-soluble powder containing Feizhucai Veterinary Grade API is manufactured by blending the API with dextrose monohydrate or lactose, citric acid or sodium bicarbonate for pH control, and sodium lauryl sulfate at 0.1–0.3% w/w as wetting agent. The dry blend is packed into aluminium foil laminate pouches or high-density polyethylene jars; dissolution is tested by adding the labelled unit dose to 1,000 mL of hard water at 20–25 °C and stirring at 60 rpm, with clarity assessed after 10 min. The final drinking water concentration is derived only from the approved summary of product characteristics, and production batch records do not assign therapeutic doses independently. On-farm dosing uses a medicator to inject a 0.5–2.0% stock solution into the drinking line; pump calibration is checked because worn piston seals have produced dosing errors above 10% in field audits. Residual chlorine can oxidize the API; if the SPC does not support simultaneous chlorination, the drinking line is flushed with clean water before and after medication. The powder must pass a 250 µm sieve without agglomeration; 1.0% w/w colloidal silicon dioxide is added as anti-caking agent for high-humidity distribution regions. Content uniformity of the reconstituted solution is tested by HPLC per USP <621>; visual dissolution in 5 min is not used as a release criterion because turbidity can mask undissolved API. Carry-over between treated and untreated flocks is managed by a 10 L clean-water flush followed by inspection of drinker nipples and line end caps. The terminal product is a water-soluble powder for broiler or layer drinking water; shelf life is assigned after long-term stability at 25 °C/60% RH and accelerated stability at 40 °C/75% RH under the approved VICH stability protocol.

When Medicated Premix Homogeneity Is Required in Swine Feed

When Feizhucai Veterinary Grade API is converted into a medicated premix for swine feed, the mixing order is more critical than total blend time because a high-potency API can segregate if added first to a fine carrier. The API is pre-blended with a portion of calcium carbonate or rice hull carrier for 5–8 min in a ribbon mixer at 40–60 rpm, then extended with the remaining carrier and 0.5–1.0% w/w anti-caking agent. The premix is designed for final feed inclusion of 0.25–1.0% w/w depending on the approved SPC; the exact inclusion is set so that the main feed mixer weighing system can resolve the premix addition to ± 0.5% of batch weight. Homogeneity is tested by sampling 10 points per batch according to ISO 6497 and assaying by HPLC per USP <621>; the coefficient of variation must not exceed 5.0% for release. Carryover of medicated feed between batches is controlled with a flush sequence using 50 kg of ground maize or soybean meal after each medicated batch; residual API in the subsequent non-medicated batch is verified below the carryover limit in the marketing authorization. The finished product is a free-flowing medicated premix packaged in 25 kg multi-wall paper bags with an inner polyethylene liner; storage is maintained at ≤ 25 °C and ≤ 60% RH. If the API is sensitive to moisture, calcium carbonate carrier is dried to ≤ 0.5% w/w moisture before use; published stability data for this specific API on high-moisture feed carriers is limited, so a compatibility study is run for 30 days at 40 °C/75% RH before commercial batches are released.

For oral granules intended for swine or calves, fluid-bed granulation of Feizhucai Veterinary Grade API is selected when direct powder formulations show unacceptable dusting in the packaging area and when the API must be dispersed evenly in feed or water. The API is suspended in an aqueous binder solution containing povidone K30 at 2–5% w/w solids and sprayed from a top-spray nozzle at 1.4–1.8 bar atomizing pressure onto a fluidized charge of lactose monohydrate and maize starch in a Glatt GPCG or equivalent fluid-bed dryer. Inlet air temperature is set at 55–65 °C, product temperature is maintained at 30–38 °C, and spray rate is adjusted to hold a stable bed; if product temperature falls below 28 °C, the bed can overwet and collapse, while prolonged drying above 42 °C can darken lactose-containing granules. After spraying, granules are dried to a loss-on-drying value of 1.5–2.5% w/w and screened through a 1.0 mm sieve; fines below 75 µm are limited to ≤ 15% w/w to prevent segregation during sachet filling. Particle size distribution is measured by sieving per USP <786>, and dissolution is evaluated in 900 mL 0.1 N hydrochloric acid with USP <711> Apparatus 2 at 50 rpm. The terminal product is an oral granule for swine or calves, filled into aluminium foil-lined sachets under ≤ 40% RH. Residual moisture in tropical distribution is controlled with silica gel desiccant packs; incompatibility with hygroscopic excipients is more severe in this route because the aqueous granulation step introduces water directly, so the API is challenged in solution at 40 °C/75% RH before the aqueous binder route is locked.

Preservative Challenge Testing Determines Oral Solution Fill Limits

At bench scale, oral solution development with Feizhucai Veterinary Grade API starts with dissolving or dispersing the API in purified water containing propylene glycol at 5–15% v/v and a preservative system selected from methylparaben, propylparaben, or potassium sorbate. The solution pH is adjusted after API dissolution with citrate or phosphate buffer; unbuffered solutions have shown pH drift above 0.5 pH units during stability when the API has weak acid or weak base functionality. Preservative efficacy is tested per Ph. Eur. 5.1.3 or USP <51> using an inoculum of 10⁵–10⁶ CFU/g; if the formulation fails the challenge test after 14 days, the preservative concentration is raised only within the approved regulatory range because excessive preservative can cause palatability rejection in calves. The solution is filled into amber Type III glass or high-density polyethylene bottles with tamper-evident closures; amber glass is mandatory if the API solution shows spectral absorbance above 0.2 AU between 320 nm and 450 nm measured by USP <857> ultraviolet-visible spectrophotometry. In-use stability is evaluated by withdrawing 5 mL samples daily for 7 days from a 1 L bottle stored at 25 °C/60% RH; assay and microbial quality must remain within specification throughout the in-use period. The terminal product is an oral solution for calves, pigs, or poultry with a calibrated dosing cup or graduated syringe; the delivery device is verified to deliver at least ± 5% of the labelled dose at the minimum graduation. If the API is poorly water-soluble, published data for this specific oral solution configuration is limited, so solubilization studies are run at 20–25 °C with pH ranging from 3.0 to 7.0 before the formulation is frozen for scale-up.